Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03529773 · ClinicalTrials.gov registry record · Phase 2
A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,235
- Enrollment target
NCT03529773: Completed Phase 2 study, sponsored by Pfizer.
NCT03529773 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 1,235 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (829% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03529773, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,235 participants
- Enrollment target
Study Summary
The study will describe the safety, tolerability, and immunogenicity of up to 6 RSV vaccine formulations when administered alone or concomitantly with seasonal inactivated influenza vaccine (SIIV).
Primary Outcome
Local reactions included pain at injection site, redness and swelling recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: 2.5 to 5.0 cm, moderate: greater than (\>) 5.0 to 10.0 cm and severe: \>10 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfere with daily activity and severe: prevented daily ac
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Formulation A
- BIOLOGICAL Formulation B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,235 participants |
| Start Date | 2018-04-18 |
| Est. Completion | 2020-12-28 |
| Phase | Phase 2 |
What the finished NCT03529773 record still lists
NCT03529773 is an interventional study that assigns participants to a tested intervention. Its 1,235 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (829% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03529773 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03529773 about?
NCT03529773 is a clinical study titled "A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults". The study will describe the safety, tolerability, and immunogenicity of up to 6 RSV vaccine formulations when administered alone or concomitantly with seasonal inactivated influenza vaccine (SIIV).
What is the current status of trial NCT03529773?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,235 participants. The study started on 2018-04-18. Estimated completion is 2020-12-28.
What interventions are being tested in trial NCT03529773?
The interventions under investigation include: Placebo (BIOLOGICAL), Formulation A (BIOLOGICAL), Formulation B (BIOLOGICAL).
Who is sponsoring clinical trial NCT03529773?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03529773's enrollment target sits among peer trials
1,235 16th of 2000 higher than 1,985 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05456841 · 1,232 participants · NA
Empathic Communication Skills (ECS) Training
- NCT05946044 · 1,230 participants · NA
The Osteoarthritis Prevention Study
- NCT06787937 · 1,230 participants · NA
Communicating About Nicotine Reduction in Cigarettes
- NCT06368245 · 1,244 participants
Durability of Suppl. Rod Constructs-SuppleMentAry Rod Technique for Long-segment Posterior Instrumented Spinal Fusions
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI